Faeth reports 33% confirmed response rate for PIKTOR-paclitaxel in Phase 2 endometrial cancer trial

Bitget2026/11/09 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Faeth Therapeutics reported positive preliminary Phase 2 results for PIKTOR with paclitaxel in previously treated advanced endometrial cancer.
The ongoing trial showed tumor responses and disease control, with some responses deepening during treatment.
Treatment-related side effects led to few discontinuations; no treatment-related deaths occurred.
Results support plans to advance into a Phase 3 registrational trial, subject to regulatory alignment.
Management will discuss the findings during a webcast today at 8 a.m. ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611090700BIZWIRE_USPR_____20261109_BW063698) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Faeth reports 33% confirmed response rate for PIKTOR-paclitaxel in Phase 2 endometrial cancer trial

You may also like

Crypto prices